Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

Table 2 Effectiveness of three consecutive monthly doses of Credelio Plus^® and afoxolaner + milbemycin oxime based on investigator counts of natural flea infestations for all flea species on client owned dogs in European field study

Study day	Treatment group	n	Live flea counts		% Effectiveness
Study day	Treatment group	n	Range	Arithmetic mean	% Effectiveness
0	Credelio Plus^®	135	5–100	11.8	–
	Afoxolaner + Milbemycin oxime	67	5–139	11.4	–
14 ± 2	Credelio Plus^®	130	0–12	0.15	98.7
	Afoxolaner + Milbemycin oxime	66	0–6	0.17	98.5
28 ± 2	Credelio Plus^®	132	0–3	0.05	99.6
	Afoxolaner + Milbemycin oxime	66	0–20	0.32	97.2
56 ± 2	Credelio Plus^®	131	0–0	0	100
	Afoxolaner + Milbemycin oxime	65	0–3	0.05	99.6
84 ± 2	Credelio Plus^®	126	0–0	0	100
	Afoxolaner + Milbemycin oxime	65	0–0	0	100

ISSN: 1756-3305